3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
11
Carcinoma, Intraductal, Noninfiltrating
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Pain
2
Neoplasms
2
Breast Carcinoma In Situ
2
Arthralgia
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Radiation Injuries
1
Psoriasis
1
Prostatic Neoplasms
1
Peripheral Nervous System Diseases
1
Pelvic Inflammatory Disease
1
Ovarian Neoplasms
1
Osteoarthritis
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Malnutrition
1
Lymphoma
1
Leukemia
1
Fatigue
1
Dyspareunia
1
Colonic Neoplasms
1
Breast Neoplasms, Male
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Interventions
Data Collection
3
telitacicept
1
human papillomavirus vaccine, L1 type 16, 18
1
Vitamin D
1
Telemedicine
1
Plasma Exchange
1
Mycophenolic Acid
1
Immune Checkpoint Inhibitors
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Docosahexaenoic Acids
1
Cholecalciferol
1
CT-P13
1
Azathioprine
1
Ashwagandha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Autoimmune Diseases
×
Fatty Acids, Omega-3
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts